Head-to-head analysis: Cyclo Therapeutics (NASDAQ:CYTH) and Suic Worldwide (OTCMKTS:SUIC)


Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) and Suic Worldwide (OTCMKTS:SUIC – Get Rating) are both small cap medical companies, but which is the best investment? We’ll compare the two companies based on earnings strength, profitability, valuation, institutional ownership, dividends, risk, and analyst recommendations.

Profitability

This table compares the net margins, return on equity and return on assets of Cyclo Therapeutics and Suic Worldwide.

Net margins Return on equity return on assets
Cyclo Therapeutic -915.04% -109.71% -85.69%
Suic in the world 0.83% -6.57% 0.71%

Risk and Volatility

Cyclo Therapeutics has a beta of -0.75, suggesting its stock price is 175% less volatile than the S&P 500. By comparison, Suic Worldwide has a beta of 0.56, suggesting its stock price is 44 % less volatile than the S&P 500.

Valuation and benefits

This table compares revenue, earnings per share (EPS), and valuation of Cyclo Therapeutics and Suic Worldwide.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Cyclo Therapeutic $1.59 million 11.12 -$14.29 million ($1.83) -1.15
Suic in the world $380,000.00 29.54 $10,000.00 N / A N / A

Suic Worldwide has lower revenues, but higher profits than Cyclo Therapeutics.

Institutional and insider ownership

7.1% of Cyclo Therapeutics shares are held by institutional investors. 12.3% of Cyclo Therapeutics shares are held by insiders. Strong institutional ownership indicates that large fund managers, hedge funds, and endowments believe a stock is poised for long-term growth.

Analyst Notes

This is a breakdown of the current ratings and recommendations for Cyclo Therapeutics and Suic Worldwide, as provided by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Cyclo Therapeutic 0 0 1 0 3.00
Suic in the world 0 0 0 0 N / A

Cyclo Therapeutics currently has a consensus price target of $16.00, suggesting a potential upside of 661.90%. Given Cyclo Therapeutics’ likely higher upside, analysts clearly believe Cyclo Therapeutics is more favorable than Suic Worldwide.

Summary

Suic Worldwide beats Cyclo Therapeutics on 6 out of 11 factors compared between the two stocks.

Cyclo Therapeutics Company Profile (Get a rating)

Cyclo Therapeutics, Inc., a clinical-stage biotechnology company, develops cyclodextrin products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is in phase III clinical trials for the treatment of Niemann-Pick type C disease. The company is also developing Trappsol Cyclo for the treatment of Alzheimer’s disease. Additionally, it sells cyclodextrins and related products to the pharmaceutical, nutritional and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

Global Suic Company Profile (Get a rating)

Sino United Worldwide Consolidated Ltd. provides IT management consulting services. The company was previously known as AJ Greentech Holdings Ltd. and changed its name to Sino United Worldwide Consolidated Ltd. in July 2017. Sino United Worldwide Consolidated Ltd. was incorporated in 2006 and is headquartered in Flushing, New York.



Get news and reviews for Cyclo Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Cyclo Therapeutics and related companies with MarketBeat.com’s FREE daily newsletter.

Valerie J. Wallis